A meta-analysis exploring factors associated with quality of life in first-episode psychosis provides guidance and take-home points for clinicians.
Brian Miller, MD, PhD, MPH
When patients ask, “How long should I continue antipsychotic treatment after the first episode of schizophrenia?”, consider this 20-year follow-up study.
ECT is a highly effective treatment for depression, but a portion of patients fail to respond as hoped. Clinical variables have overall limited utility as a predictor of response. Is inflammation the key?
A gentle reminder to patients of all ages to “get moving” may go a long way in decreasing the risk of future depression.
A novel compound holds promise for addressing cognitive deficits in schizophrenia.
The neuroprotective role of resilience in patients with schizophrenia who experienced early childhood trauma is evaluated in this brief update.
Handgrip is a simple proxy for muscular strength and a clinically useful measure of muscular function. What are the neurophysiologic underpinnings of the relationship between handgrip strength and cognition?
Handgrip is a simple proxy for physical strength and a clinically useful measure of muscular function. What about cognitive function in patients with schizophrenia? A large study looked into just that.
Up to 50% of cases of cannabis-induced psychosis covert to schizophrenia. A new study provides striking evidence for abuse of other substances and schizophrenia onset.
Is there a link between childhood and parental asthma and risk of schizophrenia?